Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 15.05
(-3.65%)
CNY 15.05
(-3.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 860.45 Million CNY | 8.23% |
| 2022 | 752.99 Million CNY | 4.13% |
| 2021 | 723.13 Million CNY | 28.19% |
| 2020 | 564.11 Million CNY | -13.31% |
| 2019 | 650.74 Million CNY | 36.23% |
| 2018 | 477.69 Million CNY | 77.58% |
| 2017 | 269 Million CNY | 86.56% |
| 2016 | 144.19 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 165.9 Million CNY | -42.43% |
| 2024 Q2 | 178.48 Million CNY | 7.58% |
| 2024 Q3 | 217.09 Million CNY | 24.56% |
| 2023 FY | 814.93 Million CNY | 8.23% |
| 2023 Q1 | 212.78 Million CNY | 9.97% |
| 2023 Q2 | 158.97 Million CNY | -25.29% |
| 2023 Q3 | 154.96 Million CNY | -2.53% |
| 2023 Q4 | 288.21 Million CNY | 85.99% |
| 2022 Q4 | 193.49 Million CNY | 9.26% |
| 2022 Q1 | 211.38 Million CNY | -27.63% |
| 2022 Q3 | 177.1 Million CNY | 3.56% |
| 2022 Q2 | 171.01 Million CNY | -19.1% |
| 2022 FY | 752.99 Million CNY | 4.13% |
| 2021 Q3 | 135.6 Million CNY | -11.51% |
| 2021 Q1 | 142.21 Million CNY | -12.59% |
| 2021 FY | 723.13 Million CNY | 28.19% |
| 2021 Q4 | 292.08 Million CNY | 115.4% |
| 2021 Q2 | 153.23 Million CNY | 7.75% |
| 2020 Q3 | 103.65 Million CNY | -35.2% |
| 2020 Q4 | 162.68 Million CNY | 56.95% |
| 2020 FY | 564.11 Million CNY | -13.31% |
| 2020 Q1 | 137.82 Million CNY | -24.41% |
| 2020 Q2 | 159.95 Million CNY | 16.06% |
| 2019 Q1 | 142.88 Million CNY | 0.0% |
| 2019 FY | 650.74 Million CNY | 36.23% |
| 2019 Q2 | 177.53 Million CNY | 24.25% |
| 2019 Q4 | 182.33 Million CNY | 23.19% |
| 2019 Q3 | 148 Million CNY | -16.63% |
| 2018 FY | 477.69 Million CNY | 77.58% |
| 2017 FY | 269 Million CNY | 86.56% |
| 2016 FY | 144.19 Million CNY | 0.0% |